Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

y from increased spending on AZ-004 and AZ-104 as the Company continued development of these product candidates under the Symphony Allegro agreement, increased spending on AZ-003 with continued development of this product candidate under the development agreement with Endo Pharmaceuticals, increased spending for device development and manufacturing process scale-up efforts, increased personnel-related costs to support these efforts, and increased share-based compensation costs.

On January 1, 2006, Alexza adopted FAS 123R and reports employee share-based compensation expense based on the fair value of the award. Share-based compensation was $1,447,000 and $2,638,000 in the quarter and six month period ended June 30, 2008 compared to $557,000 and $1,276,000 in the comparable periods in 2007. Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc., its variable interest entity. As the Company has no direct ownership in Allegro, it reduces its net loss by the losses incurred by Allegro. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the quarter and six month period ended June 30, 2008 by $5.9 million and $9.6 million, and reduced net loss by $2.6 million and $4.7 million in the comparable periods in 2007.

Product Candidates Development Update

-- AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. In June 2008, the Company completed enrollment in its first Phase 3 clinical trial of 344 schizophrenic patients with acute agitation at 24 U.S. clinical centers. The trial was an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and tested AZ-004 at two dose levels, 5 and 10 mg. Patients received up to three doses of study drug in a 24-hour period, depending on their clinical status. The primary endpoint for the study is the change from baseline in the PAN
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... OAKLAND, Calif. , May 20, 2013  Whole-cell ... than acellular pertussis vaccines during a large recent outbreak, ... Pediatrics. Whole-cell pertussis vaccines, also called DTwP, ... associated with safety concerns that ultimately led to the ... DTaP. By the late 1990s, the United ...
(Date:5/18/2013)... ORLANDO, Fla. , May 18, 2013 ... and are considered the most sensitive method for ... completely effective in preventing cancer cases 3 . EndoChoice ... its new Fuse™ system significantly improves the accuracy of ... missed by colonoscopists. EndoChoice will be discussing these clinical ...
(Date:5/18/2013)... , May 18, 2013 Faruqi & ... is investigating potential securities fraud at AVEO Pharmaceuticals, ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by issuing ... Phase III drug trials for Tivopath (tivozanib) (titled ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... Aug. 16 Adeona Pharmaceuticals, Inc. (AMEX: AEN ... recent achievements. Adeona will hold a conference ... discuss these results. James S. Kuo, M.D., M.B.A., Adeona,s Chief ... please call toll free: 1-800-860-2442 (US); international dial-in: ...
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
Cached Medicine Technology:Adeona Announces Second Quarter 2010 Profitability and Achievements 2Adeona Announces Second Quarter 2010 Profitability and Achievements 3Adeona Announces Second Quarter 2010 Profitability and Achievements 4Adeona Announces Second Quarter 2010 Profitability and Achievements 5Adeona Announces Second Quarter 2010 Profitability and Achievements 6Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2
(Date:5/20/2013)... 20, 2013 In order to prepare for ... wellness team from DrSmartphoneMD launched an article series to raise ... The series launched with the precautions that need ... the DrSmartphoneMD program are not one of the 3.5 million ... more than 90% of all skin cancer cases are associated ...
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 ... just been released to the public creating a ... gain access to this elite business training. WealthSpringMarketing.com's ... course as well as an exclusive bonus. , ... for providing elite business training to individuals serious ...
(Date:5/20/2013)... 2013 Parker Waichman LLP, a national ... injured by defective drugs, has filed a lawsuit on ... use of the diabetes drug medication Actos (pioglitazone) ... April 30, 2013, in the U.S. District Court for ... it is one of thousands of cases pending in ...
(Date:5/20/2013)... West Palm Beach, FL (PRWEB) May 20, 2013 ... Schwartz is honored to be recognized as a “Top Doc” ... of The Palm Beacher Magazine. , The Palm Beacher ... published a list of “Top Docs” in the May/June 2013 ... specialties. Featuring the best restaurants and dining, events, things to ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Mirena ... in the multidistrict litigation recently established in U.S. District ... reports. According to court records, the litigation’s first ... time appointments to Plaintiff’s leadership positions were discussed. ... in the Southern District of New York, all of ...
Breaking Medicine News(10 mins):Health News:Combat Skin Cancer In Summer Months 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3
... advertises during shows watched by typical U.S. teens, analysis ... TV shows that attract a significant proportion of teenage ... for alcohol, new research has found. , Using Nielsen ... for alcohol that aired on cable TV from 2001 ...
... ... , with the influx of new patients entering the healthcare system under Obama,s proposed ... ... Journal of General Internal Medicine, healthcare planners projected that physician surpluses of both U.S. ...
... ... ready to heat and eat meals, are applauding the recent TIME magazine cover story that ... properly balanced meals. , ... VA (PRWEB) August 29, 2009 -- Officials at Diet-to-Go, a national leader in deliciously healthy, ...
... untreated Ugandans infected with type D were affected, study ... subtype of HIV a person has may determine their ... report. , Cognitive difficulties, even dementia, are a common ... Africa, researchers led by Dr. Ned Sacktor noted that ...
... , , , , ... 1 , , HARRISBURG, Pa., Aug. 28 ... people who live or work within a 10-mile radius of Pennsylvania,s five nuclear ... tablets that were distributed previously by the commonwealth will expire on Aug. 31 ...
... help physicians predict a patient,s risk of dying from chronic ... assess the severity of a patient,s illness to determine the ... bronchitis, is a major public health problem and it is ... study of the ADO index is published in the August ...
Cached Medicine News:Health News:Alcohol Ads on Cable TV Reach Young Audiences 2Health News:Alcohol Ads on Cable TV Reach Young Audiences 3Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 2Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 3Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 2Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 3Health News:Pennsylvania Health Department Distributing Potassium Iodide to People Living, Working Near Nuclear Power Plants 2Health News:Pennsylvania Health Department Distributing Potassium Iodide to People Living, Working Near Nuclear Power Plants 3Health News:New tool to predict the risk of death in COPD may help physicians to individualize treatment 2
... of three software components that comprise ... ,Three software components comprise the SmartPill ... software, SmartPill Data Receiver software and ... are integrated and indispensable parts of ...
... Analysis for POLYGRAM NET™ works with the ... analyze multichannel EGG signals. The EGG analysis ... by performing an automatic electrode impedance check ... beginning of a recording. If the electrode ...
... the foundation and supporting framework for ... extremely versatile software supports the reporting, ... the GI diagnostic testing procedures including ... ambulatory pH testing, esophageal manometry, bile ...
Symbia T, a TruePoint SPECTCT system, combines a dual-detector variable angle gamma camera with a CT scanner optimized for rapid, accurate attenuation correction of the nuclear data....
Medicine Products: